Gilead Sciences (GILD) “might end up doing nothing in oncology” if the right takeover deal doesn’t present itself, Chief Executive John Milligan reportedly told an analyst Wednesday.
The third-largest biotech by market cap, Gilead has struggled with declining sales of hepatitis C drugs for several quarters. In the first quarter, Gilead hinted that it could be looking to buy an oncology player. But Gilead remained mum on a potential merger in the recent second quarter.
